Revolution Medicines, Inc. filings document a late-stage clinical oncology company focused on RAS-addicted cancers and RAS(ON) inhibitors. Its Form 8-K reports include financial results, clinical-program updates for daraxonrasib and other pipeline candidates, regulatory-related disclosures and material events tied to corporate progress.
The company’s SEC record also covers proxy governance, annual meeting matters, executive compensation, registered securities and capital-structure changes. Disclosures identify Nasdaq-listed common stock and warrants, and material-agreement filings describe convertible senior notes due 2033, related indenture terms and other financing arrangements used to support research and development, administrative expenses and potential commercialization activities.
Revolution Medicines, Inc. (RVMD) reported that officer Stephen Michael Kelsey filed a notice of proposed sale under Rule 144 for 5,415 shares of common stock expected from RSU vesting on September 15, 2026, to be held at E*TRADE Financial Corporation.
The notice also lists recent sales of Revolution Medicines common stock for Kelsey’s account, including 92,531 shares on September 11, 2026 with a transaction value of $18,724,767.48, and 4,175 shares on June 16, 2026 with a transaction value of $651,797.66.
Revolution Medicines, Inc. (RVMD) is named in a notice that officer Margaret A. Horn has filed under Rule 144 for a proposed sale of common stock. The filing reports an intent to sell 4,830 shares of RVMD common stock on or after September 15, 2026, following RSU vesting for services rendered.
The notice also lists prior sales of RVMD common stock by Horn during the preceding three months, providing share counts and dollar amounts for each transaction. Jack Anders signed the notice as attorney-in-fact for Margaret A. Horn.
Revolution Medicines, Inc. (RVMD) is the issuer of common stock that Mark A. Goldsmith plans to sell under Rule 144. A notice covers the proposed sale of 13,603 shares tied to RSU vesting on September 15, 2026, with an indicated aggregate market value of about $2,771,883.31. The notice also lists prior Rule 144 sales in the past three months by Goldsmith and related revocable trusts.
Revolution Medicines, Inc. (RVMD) is the issuer for a Rule 144 notice filed on behalf of officer Jeff Cislini covering potential sales of company common stock. The notice lists 3,272 shares to be sold through E*TRADE Financial Corporation in connection with RSU vesting on September 15, 2026, for services rendered.
The filing also reports prior sales of company common stock by Jeff Cislini during the past three months, including 56,894 shares on August 21, 2026 and 2,157 shares on June 16, 2026.
Revolution Medicines, Inc. (RVMD) has an officer, Jack Anders, filing a notice of proposed sale of common stock under Rule 144. The notice covers 3,939 shares of common stock, to be sold through E*TRADE Financial Corporation on or about September 15, 2026, with an indicated aggregate market value of $802,650.03.
The shares to be sold arise from RSU vesting from the issuer as compensation for services rendered. The filing also reports prior sales in the last three months: 20,000 shares of common stock on June 24, 2026 for $3,366,604.46 and 2,722 shares on June 16, 2026 for $424,956.46.
Revolution Medicines, Inc. (RVMD) reported that senior advisor to the CEO Stephen Michael Kelsey exercised stock options for a total of 92,531 shares of Common Stock on September 11, 2026, at exercise prices of $42.45 and $40.74 per share and sold 92,531 shares in multiple transactions at prices around $200 per share. The transactions were made pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026, and reported sale prices reflect weighted average prices for trades executed within specified intraday ranges.
Revolution Medicines, Inc. (RVMD) reported that Chief Global Commercialization Officer Anthony Mancini exercised options and sold shares on September 10, 2026 under a pre-arranged Rule 10b5-1 trading plan. He exercised 9,363 stock options at an exercise price of $33.62 per share, acquiring the same number of common shares, and sold an aggregate of 15,448 common shares in multiple trades at weighted-average prices around $203–$207 per share. Following the option exercise, he held 96,746 stock options and his equity position also includes 43,700 restricted stock units, which are subject to time-based vesting through April 2029.
Revolution Medicines, Inc. (RVMD) shareholder and officer Stephen Kelsey filed a notice of proposed sales of common stock under Rule 144. The notice covers up to 92,531 shares of RVMD common stock, with an indicated aggregate market value of $18,816,178.85, to be sold beginning on or about September 11, 2026 on NASDAQ.
The shares were and will be acquired through the exercise of stock options for cash over the next three months, with the dates of acquisition and payment matching the dates of exercise and sale. Kelsey also reported a prior sale of 4,175 shares on June 16, 2026.
Revolution Medicines, Inc. (RVMD) director Lorence H. Kim reported indirect sales of common stock held by the Lorence Kim Revocable Trust. On September 8, 2026, the trust sold 17,090 shares of RVMD common stock in multiple open-market transactions at weighted-average prices within specified ranges, pursuant to a Rule 10b5-1 trading plan adopted on June 1, 2026. Separately, Kim continues to hold 1,191 restricted stock units directly.
Revolution Medicines, Inc. (RVMD) received a notice under Rule 144 that officer Anthony Mancini plans to sell common stock through Morgan Stanley Smith Barney. The notice covers up to 15,448 shares of common stock, with an aggregate market value of $3,208,240.64, in a transaction expected on September 10, 2026.